Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

INTRODUCTION: Antiviral drugs have shown limited effectiveness in treating patients with coronavirus disease 2019 (COVID-19). We aimed to assess the effects of a favipiravir and hydroxychloroquine combination on treating moderate-to-severe COVID-19 patients. METHODS: An investigator-initiated, multi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Infect Dis Ther
Autori principali: Bosaeed, Mohammad, Mahmoud, Ebrahim, Alharbi, Ahmad, Altayib, Hadeel, Albayat, Hawra, Alharbi, Faisal, Ghalilah, Khalid, Al Arfaj, Abdulmajid, AlJishi, Jumana, Alarfaj, Abdullatif, Alqahtani, Hajar, Almutairi, Badriah M., Almaghaslah, Manar, Alyahya, Nawaf M., Bawazir, Abdullah, AlEisa, Saud, Alsaedy, Abdulrahman, Bouchama, Abderrezak, Alharbi, Malak, AlShamrani, Majid, Al Johani, Sameera, Aljeraisy, Majed, Alzahrani, Mohammed, Althaqafi, Abdulhakeem O., Almarhabi, Hassan, Alotaibi, Athari, Alqahtani, Nasser, Arabi, Yaseen M., Aldibasi, Omar S., Alaskar, Ahmad
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Healthcare 2021
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8316887/
https://ncbi.nlm.nih.gov/pubmed/34319552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-021-00496-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi